Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
A Tissue-Engineered Approach to Investigate Corneal Permeability in a 3D hemi-cornea Model
Author Affiliations & Notes
  • Franziska Seifert
    Ophthalmology, Universitatsklinikum Wurzburg Augenklinik und Poliklinik, Wurzburg, Bayern, Germany
  • Ann-Katrin Regensburger
    Ophthalmology, Universitatsklinikum Wurzburg Augenklinik und Poliklinik, Wurzburg, Bayern, Germany
  • Malik Salman Haider
    Ophthalmology, Universitatsklinikum Wurzburg Augenklinik und Poliklinik, Wurzburg, Bayern, Germany
  • Jost Hillenkamp
    Ophthalmology, Universitatsklinikum Wurzburg Augenklinik und Poliklinik, Wurzburg, Bayern, Germany
  • Daniel Kampik
    Ophthalmology, Universitatsklinikum Wurzburg Augenklinik und Poliklinik, Wurzburg, Bayern, Germany
  • Footnotes
    Commercial Relationships   Franziska Seifert None; Ann-Katrin Regensburger None; Malik Salman Haider None; Jost Hillenkamp None; Daniel Kampik None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 4477. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Franziska Seifert, Ann-Katrin Regensburger, Malik Salman Haider, Jost Hillenkamp, Daniel Kampik; A Tissue-Engineered Approach to Investigate Corneal Permeability in a 3D hemi-cornea Model. Invest. Ophthalmol. Vis. Sci. 2024;65(7):4477.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Corneal permeability determines the efficacy of drugs inside the eye. As an alternative to animal testing, we developed and validated a tissue-engineered 3D cornea model (based on human cells) with permeability assays using low and high molecular weight pharmaceuticals.

Methods : The 3D hemi-cornea model consists of a multilayered epithelium of primary epithelial cells from human donor corneas and a stroma equivalent of 45,000 primary human keratocytes in collagen, embedded in a snapwell insert (0.4 µm pore size) (700 µL type I collagen (10.5 mg/mL), compression to 159 µL∼500 µm thickness). Due to the firm adhesion of the model with the insert wall, the apical and basolateral sides are separated. After 8 days of cultivation at the air-liquid interface, histological examination showed a multilayered, nonkeratinized squamous epithelium on the stroma. The test substances used were FITC (fluorescein isothiocyanate)-dextran (4k Da, 0.3 mg/ml), fluorescein sodium (376 Da, 0.002 %), ofloxacin (3 mg/ml) and amphotericin B (0.5 mg/ml) applied apically to the model. After 24 h, fluorescence and absorption in the apical and basolateral medium were measured using a photometer (TECAN Infnite) and UV/VIS-spectrometer (FLUOstarOmega), respectively. The diffusion was calculated as the ratio of the absorption of the basolateral medium to the absorption of the apical medium. To examine the impact of the epithelium as a diffusion barrier, it was removed with EDTA.

Results : In the 3D hemi-cornea model, a statistically significant lower permeability was observed for the high-molecular weight FITC-dextran compared to fluorescein sodium. With intact epithelium, a diffusion of 0.97 % ± 0.05 % was found for FITC-dextran and 7.57 % ± 2.06 % for fluorescein sodium. After the removal of epithelial barrier by EDTA, FITC-dextran showed an approximately 4.8-fold (4.69 % ± 1.38 %) and fluorescein sodium a 2.5-fold higher diffusion (18.58 % ± 4.11 %) compared to intact epithelium. While amphotericin B could not be detected in the basolateral medium, ofloxacin showed a diffusion of 86 % with intact and 88.7 % with removed epithelial barrier.

Conclusions : Our 3D hemi-cornea model represents a promising in vitro system for measuring permeability. The low standard deviation shows a high reproducibility of the data and facilitates testing different formulations of drugs, reducing the need for animal or human tissue.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×